Background: Currently, the acquisition of tissue from metastatic deposits is not recommended as a routine practice.
introduction
Determination of hormone receptors [estrogen receptor (ER) and progesterone receptor (PgR)] and human epidermal growth factor receptor 2 (HER2) status in the primary tumor is clinically relevant to define the breast cancer subtypes [1] , the clinical outcome [2] , and the choice of therapy [3] . Currently, the acquisition of tissue from metastatic deposits is not recommended as a routine practice. As a consequence, the therapeutic decisions for the treatment in the metastatic setting are based on the features of the primary tumor. Since biopsies are diagnostic and changes of biological features between the primary and the secondary tumors can occur, the routine biopsy of metastatic disease needs to be considered. We evaluated the occurrence of ER, PgR, and HER2 discordance in liver metastases from a retrospective series of breast cancer patients. We also assessed clinical relevance of these biological modifications by analyzing impact on treatment choice of metastatic disease.
patients and methods
We collected information through the institutional clinical-radiological database on all consecutive breast cancer patients who underwent ultrasound-guided liver biopsy at the European Institute of Oncology (IEO), Milan, Italy, between August 1999 and March 2009.
Data obtained from 1250 patients with liver metastases from any solid tumor were evaluated for this study. Inclusion characteristics comprised diagnosis of primary, unilateral breast cancer with development of liver recurrent disease and recorded expression status of ER, PgR, and HER2 in both primary tumor and liver metastasis. Exclusion criteria comprised bilateral breast cancer, male gender, and ductal carcinoma in situ as initial diagnosis, and patients with synchronous metastases were excluded. Patients could have any form of surgical, systemic (neoadjuvant and adjuvant, previous lines for metastatic disease) therapy as well as radiotherapy. The institutional review board approved this retrospective chart review, and all patients provided an informed consent.
Data on patients' medical history, concurrent diseases, type of surgery, and pathological assessment of morphological and biological features were collected. Primary tumors were classified histologically according to the World Health Organization Histological Classification of Breast Tumors, as modified by Rosen and Obermann [4] . Tumor grading was assessed according to Elston and Ellis [5] . ER and PgR status were assessed. HER2 immunohistochemical (IHC) expression was evaluated using a 1 : 400 dilution of a polyclonal antiserum (Dako, Glostrup, Denmark). IHC expression was scored as follows: 0 (no staining or faint membrane staining), 1+ (faint membrane staining in >10% of tumor cells, incomplete membrane staining), 2+ (weak to moderate membrane staining in >10% of tumor cells), and 3+ (intense circumferential membrane staining in >10% of tumor cells). For this analysis, HER2 scores of 0 and 1+ were considered negative. HER2 IHC 3+ and FISH-amplified tumors were considered positive. All IHC 2+ tumors and tumors for which IHC was not assessable were also tested for gene amplification by FISH (Vysis PathVysion; Abbott, Chicago, IL). Slides were hybridized with probes to locus-specific identifier HER-2/neu and chromosome 17 enumeration probe (CEP17) with the PathVysion HER-2 DNA Probe Kit according to the manufacturer's instructions. Scoring was carried out according to the manufacturer's guidelines, and the HER-2/CEP17 ratio was calculated. A HER-2/CEP17 ratio greater than or equal to two was considered evidence of gene amplification.
Clinical and pathological data were entered by medical oncologists into a 'user-friendly' database designed with Microsoft Access Ò and checked by a data manager and a quality data reviewer. We identified all patients for whom biological features of disease (ER, PgR, and HER2) on primary tumor and liver metastasis were available. The type of treatment [endocrine therapy (ET), trastuzumab, or chemotherapy] was retrospectively retrieved from medical charts.
statistical methods
Fisher's exact test was used to compare proportions. Polytomous logistic regression was used to assess the association between ER and PgR changes, considered as continuous independent variables, and HER2 status change, considered as response variable and categorized as 'change to positive', 'change to negative', and 'no change'. The category 'no change' was considered as reference. Association between variables was quantified by means of the odds ratio (OR) and its 95% confidence interval (CI). All statistical analyses were carried out with SAS software (SAS Institute, Cary, NC). All reported P values were two-sided.
results
Between August 1999 and March 2009, a total of 1250 patients with liver metastases from any solid tumor were referred to the IEO's Division of Radiology to undergo an ultrasound liver biopsy. Among this population, we identified a total of 255 consecutive female patients with breast cancer with matched primary tumor and liver tissue samples for whom biological features of disease were available.
The baseline demographic and pathological characteristics, and systemic treatments are listed in Table 1 . Sixteen patients had liver synchronous metastases: of note, 97% of the remaining patients received a treatment before liver biopsy.
According to histology of the primary infiltrating tumor, 91.5% (n = 225) cases were ductal and 5.7% (n = 14) lobular carcinomas. Two hundred three patients (79.6%) had an endocrine-responsive tumor expressing ER and/or PgR. HER2 overexpressed/amplified status was detected in 54 (30.4%) of the primary tumors. Median time from primary diagnosis to liver biopsy was 3.4 years (range 0-18.3 years). All patients underwent liver biopsy. One hundred fifty-two (60.6%) patients had only metastatic liver disease, whereas 60 (23.9%) had two sites and 39 (15.5%) had three or more sites of metastatic disease. We also assessed the discordance rate in patients for whom ER and HER2 receptor status were both assessed at IEO either on primary tumor or on liver metastases. Cases available for discordance's analysis were 153 for ER status and 90 for HER2 assessment. Changes in ER status were observed in 18 of 153 patients (13.3%; 95% CI 8.1% to 20.2%). Changes in HER2 status were observed in 15 of 90 patients (14.3%; 95% CI 8.2% to 22.5%). All discordant cases (primary tumor and metastases) were reviewed centrally with the same staining technique to reduce interlaboratory variability. Nevertheless, the observed changes were not verified by a single (blinded) pathologist, further decreasing interobserver variability.
Quantitative changes between primary tumor and liver metastases in ER and PgR levels for each patient are shown in Figure 1 . Although the marginal distributions of ER in primary tumor and liver biopsy were not statistically different, ER expression levels changed in a high proportion of cases (69.5%). Figure 2 shows the association between ER and PgR changes, considered as continuous variables, and HER2 status change. Changes in HER2 status from negative to positive were significantly associated with change in ER expression (OR for 10% decrease in the percentage of positive cells between primary tumor and liver biopsy: 1.30; 95% CI 1.02-1.65, P = 0.03). A similar trend was observed between changes in HER2 status and PgR expression (OR 1.29; 95% CI 0.98-1.69, P = 0.07).
impact of receptor status changes on treatment choice for metastatic disease Table 3 summarizes the impact of the receptor status discordance between primary tumors and liver metastases on endocrine and/or biological therapy. Patients who had liver synchronous metastases or patients with missing information about treatment before and/or after biopsy were excluded from this analysis.
Discordance in ER/PgR receptor status led to change in ET for 21 of 37 patients (56.8%), whereas 77 of 183 concordant patients (42.1%) had a change of ET or started a chemotherapy due to progressive disease (P = 0.11). Seventeen of 26 patients (65%) who changed ER/PgR status from positive to negative stopped ET after liver biopsy, whereas among the 11 patients who changed from negative to positive, 2 (18%) started ET after liver biopsy and 2 (18%) stopped ET.
Discordance in HER2 status led to change in IT for 10 of 20 patients (50.0%), whereas 24 of 116 concordant patients (20.7%) had a change of chemotherapy combined with IT (P = 0.01).
Among the 14 patients who changed HER2 status from positive to negative, 2 patients (14%) stopped IT and 2 patients (14%) continued trastuzumab with another chemotherapy after liver biopsy.
All patients (6) who changed HER2 status from negative to positive received trastuzumab after liver biopsy.
Overall, discordance in ER, PgR, and/or HER2 status between primary tumor and liver metastases led to change in ET and/or IT for 31 of 255 (12.1%) patients.
discussion
Improving and optimizing the care of patients with metastatic breast cancer relies on a thorough understanding of the biology of the disease and how it may differ between the primary and the metastatic disease setting. In early-stage breast cancer, the assessment of ER, PgR, and HER2 status is mandatory according to the standard clinical practice guidelines since their expression is pivotal in determining therapeutic options such as ET and trastuzumab [3] . Biopsy of metastatic sites of disease, unlike the primary breast disease, is not mandatory and the current default position for therapeutic decision making is based on the histopathology of the primary tumor. Our question was whether we need to reassess biology of metastatic disease or we should rely on historical snapshot of the primary tumor to select the appropriate treatment. According to our study, we should reassess biology of metastatic disease. The discordance rates for ER, PgR, and HER2 status between primary tumor and liver metastases were 14.5%, 48.6%, and 13.9%, respectively, which led to change in therapy for 31 of 255 patients (12.1%).
Other studies addressed our questions but the results are conflicting . A recent study prospectively investigated concordance in receptor status between primary tumor and distant metastases and assessed the impact of any discordance on patient management [6] . Forty women were enrolled and 35 of them underwent biopsy. Changes in hormone receptor status were observed in 40% (P = 0.003) and in HER2 status in 8% of women. Biopsy results led to a change of management in 20% of patients (P = 0.002). No major complications were reported, except some anxiety before the procedure and pain associated with the biopsy in 48% of women [6] .
In another retrospective analysis, a total of 385 patients with invasive primary breast carcinomas and paired lymph nodes were assessed for ER, PgR, and HER2 expression. Overall, 46.9% cases had discordant quantitative breast/node receptor status of at least one receptor. Many of the differences in expression between primary tumor and node metastasis are large magnitude (greater than fivefold) changes. Triple-negative phenotype changed in 23.1% of cases [7] . Finally, in another recent retrospective analysis a total of 789 patients with recurrent breast cancer were studied [8] . ER, PgR, and HER2 status were determined by IHC and/or FISH. Discordance rates for ER, PgR, and HER2 were 18.4%, 40.3%, and 13.6%, respectively. Patients with concordant receptor status had significantly better post-recurrence survival than discordant cases; patients with discordant receptor status had unfavorable survival as those with concordant triple receptor-negative breast cancer.
Major strengths of our study are several: (i) this is a mono-institutional study with pathology and IHC carried out within the same Division of Pathology; (ii) all biopsies have been carried out in our institution, all determinations were assessed on liver biopsies; and (iii) all discordant cases (primary tumor and metastases) were reviewed centrally with the same staining technique to reduce interlaboratory variability. In contrast, the main limitations of our study are as follows: (i) this is a retrospective analysis; (ii) we carried out a manual scoring of ER, PgR, and HER2 that relies on inter-human variability estimating the percentage and/or intensity of reactive cells, resulting in semiquantitative and categorical variables; and (iii) the observed changes were not verified by a single (blinded) pathologist, further decreasing interobserver variability.
Discordance in receptor status between primary tumor and metastatic site of disease can be related to the limited accuracy and reproducibility of receptor assays, to the sampling error in biopsy procedures (specifically in heterogeneous expression of receptors), and sometimes to a real switch in the biology of the disease [31] [32] [33] [34] .
There is emerging evidence that tumor receptor status may change dynamically during the natural history of the disease. Changes in receptor expression may occur as a consequence of transcriptional or post-transcriptional modifications in the gene expression level, which may occur spontaneously or as a consequence of clonal selection in response to chemotherapy, hormonal therapy, or immunotherapy. A recent and outstanding preclinical study screened the genomic profiles of four DNA samples from an African American patient with basal-like breast cancer: peripheral blood, the primary tumor, a brain metastasis, and a xenograft derived from the primary tumor [35] . Authors observed that the mutation frequency range narrowed in brain metastasis and xenograft, indicating that the metastatic and transplantation processes selected for cells carrying a distinct subset of the primary tumor mutation repertoire. They also observed that, although additional somatic mutations, copy number alterations and structural variations do occur during the clinical course of the disease, most of the original mutations and structural variants present in the primary tumor are propagated to the metastatic site of disease [35] . Despite this observation authors concluded that the altered mutation frequency and elevated degree of copy number alterations suggest caution when interpreting the results of such experiments.
We observed that patients with liver lesions turning to HER2 positive showed a concomitant decrease in ER and PgR expression, leading to hypothesize the occurrence of a cross talk between the pathways driven by hormone receptors and HER2, and suggesting that endocrine resistance may actually be mediated by HER2 up-regulation in vivo [36] . Changes in receptor status are also supported by data from measuring serum HER2 and circulating tumor cells, in which 25%-37% of patients converted to a positive HER2 phenotype [37] .
Similar results have been presented in the recent American Society of Clinical Oncology Meeting 2010. In one prospective trial, 258 patients underwent biopsy [38] . Discordance rates in ER, PgR, or HER2 between the primary and recurrent diseases were 13%, 28%, and 5%, respectively. In this study, the biopsy results altered management in 15.9% of patients (95% CI 11.7% to 20.9%, P £ 0.0001). In another retrospective study, including >1000 patients, discordance rate on receptor status was obtained from pathology report. ER status changed from positive to negative in 27% of patients and from negative to positive in 8% of patients [39] . Our group also addressed the issue of biopsy of other metastatic sites. We carried out a retrospective analysis on 109 patients with metastatic bone disease from primary breast cancer. All patients underwent a bone biopsy. Overall discordance rate was 20% for ER and 7% for HER2 and to led to change of therapy in 14% of patients (G. Aurilio et al., unpublished data).
Issues that may prevent clinicians proposing a biopsy in the metastatic setting include lack of resources, technical difficulties, or reluctance to undertake an invasive procedure in a patient who has advanced disease.
It is important to realize that a repeat biopsy for receptor status reevaluation has a potential to harm through a false-negative result. We should also consider that many rebiopsy procedures cannot be easy to be carried out due to potential complications and due to the need of surgical approaches. We believe that clinical judgment remains important. Clearly, one argument for biopsy of recurrent disease may be to 'first do no harm', especially if you can define a treatment relying on pathology snapshot at diagnosis. Another issue to be stressed is patient's preference to undertake an invasive procedure. The final decision will be the result of a joint decision between the patient and the physician.
In our opinion, when safe and easy to carry out, a biopsy of the metastatic lesion should be considered in all patients, particularly when there is a long interval from the first diagnosis, since it is likely to impact treatment choice. 
